Publications by authors named "E Ben-Meir"
Background: The aim of this study was to quantify mediators of neutrophilic inflammation within airway extracellular vesicles (EVs) of children treated for a cystic fibrosis (CF) pulmonary exacerbation (PEx).
Methods: EVs were isolated from stored sputum samples collected before and after antibiotic therapy for PEx between 2011 and 2013, and characterised by nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM). Western blot analysis of EV protein extracts was used for EV canonical protein markers CD63, CD9 and flotillin-1 (FLOT1), as well as neutrophil elastase (NE), myeloperoxidase (MPO) and interleukin-8.
Background: Risk factors for progression of adenovirus (AdV)-associated bronchiolitis (AdV-B) to post-infectious bronchiolitis obliterans (PIBO) are poorly defined. We aimed to investigate this in a multicenter cohort.
Methods: A multicenter hospital-based analysis included children admitted with AdV-B in Jerusalem during 2016-2022.
Background: Short palate, lung, and nasal epithelium clone 1 (SPLUNC1) is an innate defence protein that acts as an anti-microbial agent and regulates airway surface liquid volume through inhibition of the epithelial sodium channel (ENaC). SPLUNC1 levels were found to be reduced in airway secretions of adults with cystic fibrosis (CF). The potential of SPLUNC1 as a biomarker in children with CF is unknown.
View Article and Find Full Text PDFHow Should the Effects of CFTR Modulator Therapy on Cystic Fibrosis Lung Disease Be Monitored?
Am J Respir Crit Care Med
August 2022
Article Synopsis
- Treatment with the CFTR drug ivacaftor improves airway NO levels and significantly reduces sputum IL-1β concentrations in CF patients, without affecting other cytokines.
- Improved IL-1β levels correlate with better pulmonary function and NO metabolism, suggesting a link between chloride conductance, IL-1β, and airway NO production.